WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company, has announced the grant of non-qualified stock options to purchase 181,300 shares of its common stock to five new employees under its 2022 Inducement Stock Incentive Plan, effective June 1, 2025. The stock options carry an exercise price of $1.07 per share, matching the closing price of the company's stock on May 30, 2025. Each option has a ten-year term, with 25% vesting after one year of service and the remaining 75% vesting in 36 monthly installments, contingent upon continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.